Research & Innovation
Research Dashboard
Welcome to the Research and Innovation portal of Dhanvantary Institute of Pharmacy and Research. We are committed to fostering scientific inquiry, advanced computational drug design, and holistic pharmaceutical development.
3
Publications1
Patents Filed1
Industry MoUs1
Research FundingPublications
Recent high-impact research articles published by DIPR faculty in peer-reviewed national and international journals.
| Year | Title of Paper | Journal Name | Author(s) |
|---|---|---|---|
| 2026 | Sulphonamide derivatives of xanthines as β2 adrenergic receptor antagonist: Drug repurposing through molecular docking studies | Letters in Applied NanoBioScience | UAM; SK; DB |
| 2026 | APPLICATIONS OF CLICK CHEMISTRY IN ANTIMICROBIAL DRUG DISCOVERY | AMC | UAM; GP; BS |
| 2026 | Molecular Modeling Approach to Identify Natural Flavonoids as Potential Main Protease (Mpro) & ACE-2 Inhibitors for the Treatment of COVID-19 Disease | Biointerface Research in Applied Chemistry | UAM; MG; VP |
Research Review & Books/Chapters
| Year | Title of Book / Chapter | Publisher | ISBN Number |
|---|---|---|---|
| No books or chapters record found. | |||
IPR: Patents & Copyrights
| Type | Title of Invention | Application No. | Status |
|---|---|---|---|
| No IPR record found. | |||
MoU & Industry Tie-ups
DIPR collaborates with leading pharmaceutical industries and academic institutions to bridge the gap between theoretical knowledge and practical application.
| Organization Name | Nature of Collaboration | Date of MoU | Status |
|---|---|---|---|
| Ribosome Research Center Pvt. Ltd. | Joint Research & Analytical Testing | 15-Nov-2025 | Active |
Research Funding & Consultancy Projects
| Project Title | Funding Agency | Duration | Status |
|---|---|---|---|
| Design and In-silico Evaluation of Radioprotective Agents | Board of Research in Nuclear Sciences (BRNS) | 2017 - 2020 | Completed |
Code of Conduct, Ethics, and Research Policy
1. Research Policy
The Dhanvantary Institute of Pharmacy and Research (DIPR) is committed to promoting a culture of rigorous scientific inquiry. The Research Policy aims to create a conducive environment for faculty and students to undertake socially relevant, innovative, and impactful research in pharmaceutical sciences.
- Resource Allocation: Providing access to state-of-the-art computational facilities, laboratories, and extensive digital libraries.
- Seed Funding: Encouraging early-career faculty and student researchers by providing institutional seed grants for promising pilot projects.
- Collaborations: Actively fostering interdisciplinary research and securing MoUs with industries and government agencies.
2. Code of Ethics in Research
Integrity is the foundation of all academic research at DIPR. Researchers must adhere strictly to ethical guidelines to ensure the credibility of their scientific output.
- Originality & Plagiarism: All research manuscripts, thesis documents, and project reports must undergo mandatory plagiarism checks using institutional software prior to submission. Zero tolerance is applied to data fabrication and falsification.
- Authorship: Authorship must reflect true intellectual contribution to the work. Ghost authorship or honorary authorship is strictly prohibited.
- Regulatory Compliance: Any research involving biological samples, animal models, or human subjects must receive prior approval from the respective institutional ethics committees (IAEC/IEC) and adhere to CPCSEA guidelines.
3. Code of Conduct
This code establishes the standard of behavior expected from all personnel utilizing DIPR research facilities.
- Laboratory Safety: Researchers must wear appropriate Personal Protective Equipment (PPE) at all times. Toxic, neurotoxic, or hazardous chemicals must be handled strictly inside fume hoods following standard operating protocols.
- Resource Utilization: Institutional resources, software licenses (e.g., molecular docking modules), and laboratory instruments must be logged properly and used exclusively for academic and approved consultancy purposes.
- Professional Integrity: Researchers must declare any conflicts of interest regarding funding, consultancy, or intellectual property rights. A respectful, collaborative, and non-discriminatory environment must be maintained in all research interactions.